These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28827411)

  • 1. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
    Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rumi E; Gattoni E; Pieri L; Zhen H; Granier M; Assad A; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
    Blood; 2017 Oct; 130(15):1768-1771. PubMed ID: 28827411
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
    Harrison CN; Mead AJ; Panchal A; Fox S; Yap C; Gbandi E; Houlton A; Alimam S; Ewing J; Wood M; Chen F; Coppell J; Panoskaltsis N; Knapper S; Ali S; Hamblin A; Scherber R; Dueck AC; Cross NCP; Mesa R; McMullin MF
    Blood; 2017 Oct; 130(17):1889-1897. PubMed ID: 29074595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential thrombocythemia: a relative benign long-term course.
    Meisel S; Shpilberg O; Ramot B; Ben-Bassat I
    Isr J Med Sci; 1993 Apr; 29(4):190-4. PubMed ID: 8491569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
    O'Sullivan JM; Hamblin A; Yap C; Fox S; Boucher R; Panchal A; Alimam S; Dreau H; Howard K; Ware P; Cross NCP; McMullin MF; Harrison CN; Mead AJ
    Blood; 2019 Dec; 134(23):2107-2111. PubMed ID: 31578205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy.
    Treliński J; Okońska M; Robak M; Chojnowski K
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):205-9. PubMed ID: 26829283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
    Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
    Treliński J; Tybura M; Smolewski P; Robak T; Chojnowski K
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):646-51. PubMed ID: 19741509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
    Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
    Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
    Tsantes AE; Nikolopoulos GK; Tsirigotis P; Zoi K; Zomas A; Kapsimali V; Kopterides P; Chondropoulos S; Dervenoulas J; Mantzios G
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):457-62. PubMed ID: 21836466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia.
    Barosi G
    Eur J Haematol Suppl; 2007 Oct; (68):24-6. PubMed ID: 17727562
    [No Abstract]   [Full Text] [Related]  

  • 12. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
    Dua V; Yadav SP; Kumar V; Saxena R; Sachdeva A
    Int J Hematol; 2012 Dec; 96(6):810-3. PubMed ID: 23054653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.
    Carobbio A; Finazzi G; Antonioli E; Vannucchi AM; Barosi G; Ruggeri M; Rodeghiero F; Delaini F; Rambaldi A; Barbui T
    Blood; 2010 Aug; 116(7):1051-5. PubMed ID: 20479281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice.
    Reilly JT
    Eur J Haematol Suppl; 2007 Oct; (68):32-4. PubMed ID: 17727564
    [No Abstract]   [Full Text] [Related]  

  • 16. Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia.
    Watanabe N; Yasuda H; Aota Y; Ando J; Aoyama T; Tanaka M; Gotoh A; Komatsu N
    Geriatr Gerontol Int; 2015 Jun; 15(6):812-3. PubMed ID: 26031797
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversal of delirium associated with essential thrombocythemia by antiplatelet therapy.
    Campbell KM; Schubert DS
    Psychosomatics; 1992; 33(2):213-5. PubMed ID: 1557486
    [No Abstract]   [Full Text] [Related]  

  • 18. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
    Renso R; Aroldi A; Pioltelli P; Gambacorti-Passerini C; Elli EM
    Blood Cancer J; 2018 Jun; 8(6):56. PubMed ID: 29891835
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.